Your session is about to expire
← Back to Search
Brachytherapy
Vaginal Cuff Brachytherapy for Endometrial Cancer
Phase 2
Waitlist Available
Led By Scott McMeekin, MD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
The purpose of this study is to determine the progression-free survival of patients with surgically staged, Stage I-II papillary serous, clear cell, or endometrioid carcinomas with high-intermediate risk factors treated by vaginal cuff brachytherapy followed by chemotherapy.
Eligible Conditions
- Endometrial Cancer
- Serous Cystadenocarcinoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2021 Phase 2 trial • 39 Patients • NCT031894469%
Taxol Reaction
6%
Fatigue
6%
Diarrhea
6%
Anemia
6%
Peripheral Neuropathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vaginal Cuff Brachytherapy + Chemotherapy
Trial Design
1Treatment groups
Experimental Treatment
Group I: Vaginal Cuff BrachytherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vaginal Cuff Brachytherapy
2017
Completed Phase 2
~70
Find a Location
Who is running the clinical trial?
University of OklahomaLead Sponsor
466 Previous Clinical Trials
91,200 Total Patients Enrolled
6 Trials studying Endometrial Cancer
318 Patients Enrolled for Endometrial Cancer
Scott McMeekin, MDPrincipal InvestigatorUniversity of Oklahoma
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger